B. Hernando

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

A. González-Neira, G. Pita, A. Lluch, 2015, The oncologist.

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype

A. Guerrero-Zotano, R. Andrés, A. Llombart-Cussac, 2020, Nutrients.

Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.

J. García-Foncillas, S. Morales, I. Álvarez, 2012 .

Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC).

M. Ramos, J. García-Saenz, M. Muñoz, 2009, Journal of Clinical Oncology.

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

S. Servitja, R. Andrés, A. Llombart-Cussac, 2020, Breast.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.